John R. Beaver - 11 Jun 2021 Form 4 Insider Report for BIOLASE, INC (BIOLQ)

Reporting relationship: President & CEO, Director
Issuer ticker: BIOLQ
Reported as of: 11 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jun 2021, 21:35:34 UTC
Prior SEC filing: 19 May 2021
Next SEC filing: 13 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ Michael C. Carroll, attorney-in-fact for John R. Beaver

Key filing fact

John R. Beaver filed Form 4 for BIOLASE, INC (BIOLQ) on 14 Jun 2021.

Key facts

This page summarizes John R. Beaver's Form 4 filing for BIOLASE, INC (BIOLQ).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Jun 2021, 21:35.

Change

Previous filing in this sequence was filed on 19 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIOL transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +4,144,139
Change %
Price: $0.000000
Shares after: 4,144,139
Date: 11 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,144,139
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent.

Footnote F2

The restricted stock unit award fully vests and is immediately exercisable upon the filing with the SEC of the Annual Report on Form 10-K for the year ending December 31, 2023, subject to performance-based vesting criteria as established by the Compensation Committee; provided that if the price of Common Stock on such vesting date is greater than $1.40 per share, one-half of the award amount above $1.40 shall be payable on the first anniversary of the vesting date, and one-half of such amount shall be payable on the second anniversary of the vesting date.